Last reviewed · How we verify

Antiretroviral medications+Isoniazid prophylaxis

French National Agency for Research on AIDS and Viral Hepatitis · Phase 3 active Small molecule

Antiretroviral medications+Isoniazid prophylaxis is a Antiretroviral combination therapy + antimycobacterial prophylaxis Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently in Phase 3 development for HIV infection with tuberculosis co-infection or latent TB infection requiring prophylaxis, Prevention of tuberculosis in HIV-positive patients.

This combination uses antiretroviral drugs to suppress HIV replication while isoniazid prophylaxis prevents tuberculosis infection in co-infected patients.

This combination uses antiretroviral drugs to suppress HIV replication while isoniazid prophylaxis prevents tuberculosis infection in co-infected patients. Used for HIV infection with tuberculosis co-infection or latent TB infection requiring prophylaxis, Prevention of tuberculosis in HIV-positive patients.

At a glance

Generic nameAntiretroviral medications+Isoniazid prophylaxis
SponsorFrench National Agency for Research on AIDS and Viral Hepatitis
Drug classAntiretroviral combination therapy + antimycobacterial prophylaxis
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Antiretroviral medications (typically including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or integrase inhibitors) block HIV replication at multiple steps of the viral lifecycle. Isoniazid is a prodrug that inhibits mycobacterial cell wall synthesis, providing prophylactic protection against tuberculosis (TB) in HIV-positive individuals at risk of TB co-infection or with latent TB infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Antiretroviral medications+Isoniazid prophylaxis

What is Antiretroviral medications+Isoniazid prophylaxis?

Antiretroviral medications+Isoniazid prophylaxis is a Antiretroviral combination therapy + antimycobacterial prophylaxis drug developed by French National Agency for Research on AIDS and Viral Hepatitis, indicated for HIV infection with tuberculosis co-infection or latent TB infection requiring prophylaxis, Prevention of tuberculosis in HIV-positive patients.

How does Antiretroviral medications+Isoniazid prophylaxis work?

This combination uses antiretroviral drugs to suppress HIV replication while isoniazid prophylaxis prevents tuberculosis infection in co-infected patients.

What is Antiretroviral medications+Isoniazid prophylaxis used for?

Antiretroviral medications+Isoniazid prophylaxis is indicated for HIV infection with tuberculosis co-infection or latent TB infection requiring prophylaxis, Prevention of tuberculosis in HIV-positive patients.

Who makes Antiretroviral medications+Isoniazid prophylaxis?

Antiretroviral medications+Isoniazid prophylaxis is developed by French National Agency for Research on AIDS and Viral Hepatitis (see full French National Agency for Research on AIDS and Viral Hepatitis pipeline at /company/french-national-agency-for-research-on-aids-and-viral-hepatitis).

What drug class is Antiretroviral medications+Isoniazid prophylaxis in?

Antiretroviral medications+Isoniazid prophylaxis belongs to the Antiretroviral combination therapy + antimycobacterial prophylaxis class. See all Antiretroviral combination therapy + antimycobacterial prophylaxis drugs at /class/antiretroviral-combination-therapy-antimycobacterial-prophylaxis.

What development phase is Antiretroviral medications+Isoniazid prophylaxis in?

Antiretroviral medications+Isoniazid prophylaxis is in Phase 3.

What are the side effects of Antiretroviral medications+Isoniazid prophylaxis?

Common side effects of Antiretroviral medications+Isoniazid prophylaxis include Peripheral neuropathy (isoniazid-related), Hepatotoxicity, Gastrointestinal disturbances, Rash, Drug interactions.

Related